Engineering enhanced protein disaggregases for neurodegenerative disease

Prion

Volumn 9, Issue 2, 2015, Pages 90-109

  Jackrel, Meredith E ^a   Shorter, James ^a  

^a UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

Amyloid; EWSR1; FUS; Hsp104; Prion; Protein disaggregation; Protein engineering; TAF15; TDP 43; synuclein

Indexed keywords

ADENOSINE TRIPHOSPHATASE; ALPHA SYNUCLEIN; CARRIER PROTEIN; CHAPERONE; FUSED IN SARCOMA PROTEIN; HEAT SHOCK PROTEIN 104; POLYGLUTAMINE; RNA BINDING PROTEIN EWS; TAR DNA BINDING PROTEIN; AMYLOID; CALMODULIN BINDING PROTEIN; EWSR1 PROTEIN, HUMAN; HEAT SHOCK PROTEIN; HSP104 PROTEIN, S CEREVISIAE; RNA BINDING PROTEIN; SACCHAROMYCES CEREVISIAE PROTEIN;

AMYOTROPHIC LATERAL SCLEROSIS; ARTICLE; ATROPHY; BINDING AFFINITY; CHROMOSOME TRANSLOCATION; DEGENERATIVE DISEASE; DISEASE ASSOCIATION; ENVIRONMENTAL FACTOR; ENZYME ACTIVITY; FRONTOTEMPORAL DEMENTIA; GAIN OF FUNCTION MUTATION; GENE MUTATION; GENE OVEREXPRESSION; GENE SEQUENCE; HUMAN; HUNTINGTON CHOREA; LOSS OF FUNCTION MUTATION; NEUROPROTECTION; PARKINSON DISEASE; PROTEIN AGGREGATION; PROTEIN ENGINEERING; PROTEIN FOLDING; PROTEIN HYDROLYSIS; REGULATORY MECHANISM; METABOLISM; MOLECULAR MODEL;

AMYLOID; CALMODULIN-BINDING PROTEINS; HEAT-SHOCK PROTEINS; HUMANS; MODELS, MOLECULAR; NEURODEGENERATIVE DISEASES; PROTEIN ENGINEERING; PROTEIN FOLDING; RNA-BINDING PROTEINS; SACCHAROMYCES CEREVISIAE PROTEINS;

EID: 84937567559     PISSN: 19336896     EISSN: 1933690X     Source Type: Journal    
DOI: 10.1080/19336896.2015.1020277     Document Type: Article

References (182)

1. Trojanowski JQ. PENN neurodegenerative disease research-in the spirit of Benjamin Franklin. Neurosignals 2008; 16: 5-10; PMID: 18097154; http://dx. doi. org/10. 1159/000109753.
2. Cushman M, Johnson BS, King OD, Gitler AD, Shorter J. Prion-like disorders: blurring the divide between transmissibility and infectivity. J Cell Sci 2010; 123: 1191-201; PMID: 20356930; http://dx. doi. org/10. 1242/jcs. 051672.
3. Robberecht W, Philips T. The changing scene of amyotrophic lateral sclerosis. Nat Rev Neurosci 2013; 14: 248-64; PMID: 23463272; http://dx. doi. org/10. 1038/nrn3430.
4. Irwin DJ, Lee VM, Trojanowski JQ. Parkinson's disease dementia: convergence of alpha-synuclein, tau and amyloid-beta pathologies. Nat Rev Neurosci 2013; 14: 626-36; PMID: 23900411; http://dx. doi. org/10. 1038/nrn3549.
5. Goedert M, Spillantini MG. A century of Alzheimer's disease. Science 2006; 314: 777-81; PMID: 17082447; http://dx. doi. org/10. 1126/science. 1132814.
6. Bulawa CE, Connelly S, Devit M, Wang L, Weigel C, Fleming JA, Packman J, Powers ET, Wiseman RL, Foss TR, et al. Tafamidis, a potent and selective transthyretin kinetic stabilizer that inhibits the amyloid cascade. Proc Natl Acad Sci USA 2012; 109: 9629-34; PMID: 22645360; http://dx. doi. org/10. 1073/pnas. 1121005109.
7. Coelho T, Maia LF, da Silva AM, Cruz MW, Plante-Bordeneuve V, Suhr OB, Conceicao I, Schmidt HH, Trigo P, Kelly JW, et al. Long-term effects of tafamidis for the treatment of transthyretin familial amyloid polyneuropathy. J Neurol 2013; 260(11): 2802-14; PMID: 23974642; http://dx. doi. org/10. 1007/s00415-013-7051-7.
8. Coelho T, Maia LF, Martins da Silva A, Waddington Cruz M, Plante-Bordeneuve V, Lozeron P, Suhr OB, Campistol JM, Conceicao IM, Schmidt HH, et al. Tafamidis for transthyretin familial amyloid polyneuropathy: a randomized, controlled trial. Neurology 2012; 79: 785-92; PMID: 22843282; http://dx. doi. org/10. 1212/WNL. 0b013e3182661eb1.
9. de Lartigue J. Tafamidis for transthyretin amyloidosis. Drugs Today (Barc) 2012; 48: 331-7; PMID: 22645721; http://dx. doi. org/10. 1358/dot. 2012. 48. 5. 1808486.
10. Nencetti S, Rossello A, Orlandini E. Tafamidis (Vyndaqel): A Light for FAP Patients. ChemMed-Chem 2013; 8(10): 1617-9; http://dx. doi. org/10. 1002/cmdc. 201300245.
11. Said G, Grippon S, Kirkpatrick P. Tafamidis. Nat Rev Drug Discov 2012; 11: 185-6; PMID: 22378262; http://dx. doi. org/10. 1038/nrd3675.
12. Knowles TP, Vendruscolo M, Dobson CM. The amyloid state and its association with protein misfolding diseases. Nat Rev Mol Cell Biol 2014; 15: 384-96; PMID: 24854788; http://dx. doi. org/10. 1038/nrm3810.
13. Jucker M, Walker LC. Self-propagation of pathogenic protein aggregates in neurodegenerative diseases. Nature 2013; 501: 45-51; PMID: 24005412; http://dx. doi. org/10. 1038/nature12481.
14. Eisenberg D, Jucker M. The amyloid state of proteins in human diseases. Cell 2012; 148: 1188-203; PMID: 22424229; http://dx. doi. org/10. 1016/j. cell. 2012. 02. 022.
15. Guo JL, Lee VM. Cell-to-cell transmission of pathogenic proteins in neurodegenerative diseases. Nat Med 2014; 20: 130-8; PMID: 24504409; http://dx. doi. org/10. 1038/nm. 3457.
16. Prusiner SB. Biology and genetics of prions causing neurodegeneration. Annu Rev Genet 2013; 47: 601-23; PMID: 24274755; http://dx. doi. org/10. 1146/annurev-genet-110711-155524.
17. Snead D, Eliezer D. Alpha-synuclein function and dysfunction on cellular membranes. Exp Neurobiol 2014; 23: 292-313; PMID: 25548530; http://dx. doi. org/10. 5607/en. 2014. 23. 4. 292.
18. van Oosten-Hawle P, Morimoto RI. Organismal proteostasis: role of cell-nonautonomous regulation and transcellular chaperone signaling. Genes Dev 2014; 28: 1533-43; PMID: 25030693; http://dx. doi. org/10. 1101/gad. 241125. 114.
19. Hipp MS, Park SH, Hartl FU. Proteostasis impairment in protein-misfolding and-aggregation diseases. Trends Cell Biol 2014; PMID: 24946960.
20. Lindquist SL, Kelly JW. Chemical and biological approaches for adapting proteostasis to ameliorate protein misfolding and aggregation diseases: progress and prognosis. Cold Spring Harb Perspect Biol 2011; 3; PMID: 21900404; http://dx. doi. org/10. 1101/cshperspect. a004507.
21. Shorter J. Hsp104: a weapon to combat diverse neurodegenerative disorders. Neurosignals 2008; 16: 63-74; PMID: 18097161; http://dx. doi. org/10. 1159/000109760.
22. Vashist S, Cushman M, Shorter J. Applying Hsp104 to protein-misfolding disorders. Biochem Cell Biol 2010; 88: 1-13; PMID: 20130674; http://dx. doi. org/10. 1139/O09-121.
23. Kayed R, Head E, Thompson JL, McIntire TM, Milton SC, Cotman CW, Glabe CG. Common structure of soluble amyloid oligomers implies common mechanism of pathogenesis. Science 2003; 300: 486-9; PMID: 12702875; http://dx. doi. org/10. 1126/science. 1079469.
24. Cohen SI, Linse S, Luheshi LM, Hellstrand E, White DA, Rajah L, Otzen DE, Vendruscolo M, Dobson CM, Knowles TP. Proliferation of amyloidbeta42 aggregates occurs through a secondary nucleation mechanism. Proc Natl Acad Sci U S A 2013; 110: 9758-63; PMID: 23703910; http://dx. doi. org/10. 1073/pnas. 1218402110.
25. Oromendia AB, Dodgson SE, Amon A. Aneuploidy causes proteotoxic stress in yeast. Genes Dev 2012; 26: 2696-708; PMID: 23222101; http://dx. doi. org/10. 1101/gad. 207407. 112.
26. Xu J, Reumers J, Couceiro JR, De Smet F, Gallardo R, Rudyak S, Cornelis A, Rozenski J, Zwolinska A, Marine JC, et al. Gain of function of mutant p53 by coaggregation with multiple tumor suppressors. Nat Chem Biol 2011; 7: 285-95; PMID: 21445056; http://dx. doi. org/10. 1038/nchembio. 546.
27. Coelho M, Dereli A, Haese A, Kuhn S, Malinovska L, DeSantis ME, Shorter J, Alberti S, Gross T, Tolic-Norrelykke IM. Fission yeast does not age under favorable conditions, but does so after stress. Curr Biol 2013; 23: 1844-52; PMID: 24035542; http://dx. doi. org/10. 1016/j. cub. 2013. 07. 084.
28. Hill SM, Hao X, Liu B, Nystrom T. Life-span extension by a metacaspase in the yeast Saccharomyces cerevisiae. Science 2014; 344: 1389-92; PMID: 24855027; http://dx. doi. org/10. 1126/science. 1252634.
29. David DC, Ollikainen N, Trinidad JC, Cary MP, Burlingame AL, Kenyon C. Widespread protein aggregation as an inherent part of aging in C. elegans. PLoS Biol 2010; 8: e1000450; PMID: 20711477; http://dx. doi. org/10. 1371/journal. pbio. 1000450.
30. Geiler-Samerotte KA, Dion MF, Budnik BA, Wang SM, Hartl DL, Drummond DA. Misfolded proteins impose a dosage-dependent fitness cost and trigger a cytosolic unfolded protein response in yeast. Proc Natl Acad Sci U S A 2011; 108: 680-5; PMID: 21187411; http://dx. doi. org/10. 1073/pnas. 1017570108.
31. Alberti S, Halfmann R, King O, Kapila A, Lindquist S. A systematic survey identifies prions and illuminates sequence features of prionogenic proteins. Cell 2009; 137: 146-58; PMID: 19345193; http://dx. doi. org/10. 1016/j. cell. 2009. 02. 044.
32. Halfmann R, Alberti S, Lindquist S. Prions, protein homeostasis, and phenotypic diversity. Trends Cell Biol 2010; 20: 125-33.; PMID: 20071174; http://dx. doi. org/10. 1016/j. tcb. 2009. 12. 003.
33. Halfmann R, Jarosz DF, Jones SK, Chang A, Lancaster AK, Lindquist S. Prions are a common mechanism for phenotypic inheritance in wild yeasts. Nature 2012; 482: 363-8; PMID: 22337056; http://dx. doi. org/10. 1038/nature10875.
34. Suzuki G, Shimazu N, Tanaka M. A yeast prion, Mod5, promotes acquired drug resistance and cell survival under environmental stress. Science 2012; 336: 355-9; PMID: 22517861; http://dx. doi. org/10. 1126/science. 1219491.
35. True HL, Lindquist SL. A yeast prion provides a mechanism for genetic variation and phenotypic diversity. Nature 2000; 407: 477-83; PMID: 11028992; http://dx. doi. org/10. 1038/35035005.
36. Tyedmers J, Treusch S, Dong J, McCaffery JM, Bevis B, Lindquist S. Prion induction involves an ancient system for the sequestration of aggregated proteins and heritable changes in prion fragmentation. Proc Natl Acad Sci U S A 2010; 107: 8633-8; PMID: 20421488; http://dx. doi. org/10. 1073/pnas. 1003895107.
37. Cegelski L, Pinkner JS, Hammer ND, Cusumano CK, Hung CS, Chorell E, Aberg V, Walker JN, Seed PC, Almqvist F, et al. Small-molecule inhibitors target Escherichia coli amyloid biogenesis and biofilm formation. Nat Chem Biol 2009; 5: 913-9; PMID: 19915538; http://dx. doi. org/10. 1038/nchembio. 242.
38. Fowler DM, Koulov AV, Alory-Jost C, Marks MS, Balch WE, Kelly JW. Functional amyloid formation within mammalian tissue. PLoS Biol 2006; 4: e6; PMID: 16300414; http://dx. doi. org/10. 1371/journal. pbio. 0040006.
39. Fowler DM, Koulov AV, Balch WE, Kelly JW. Functional amyloid-from bacteria to humans. Trends Biochem Sci 2007; 32: 217-24; PMID: 17412596; http://dx. doi. org/10. 1016/j. tibs. 2007. 03. 003.
40. Castellano LM, Shorter J. The Surprising Role of Amyloid Fibrils in HIV Infection. Biology 2012; 1: 58-80; PMID: 24832047; http://dx. doi. org/10. 3390/biology1010058.
41. Shorter J, Lindquist S. Prions as adaptive conduits of memory and inheritance. Nat Rev Genet 2005; 6: 435-50; PMID: 15931169; http://dx. doi. org/10. 1038/nrg1616.
42. Skinner JJ, Wood S, Shorter J, Englander SW, Black BE. The Mad2 partial unfolding model: regulating mitosis through Mad2 conformational switching. J Cell Biol 2008; 183: 761-8; PMID: 19029339; http://dx. doi. org/10. 1083/jcb. 200808122.
43. Watt B, van Niel G, Fowler DM, Hurbain I, Luk KC, Stayrook SE, Lemmon MA, Raposo G, Shorter J, Kelly JW, et al. N-terminal domains elicit formation of functional Pmel17 amyloid fibrils. J Biol Chem 2009; 284: 35543-55; PMID: 19840945; http://dx. doi. org/10. 1074/jbc. M109. 047449.
44. Tuite MF, Serio TR. The prion hypothesis: from biological anomaly to basic regulatory mechanism. Nat Rev Mol Cell Biol 2010; 11: 823-33; PMID: 21081963; http://dx. doi. org/10. 1038/nrm3007.
45. True HL, Berlin I, Lindquist SL. Epigenetic regulation of translation reveals hidden genetic variation to produce complex traits. Nature 2004; 431: 184-7; PMID: 15311209; http://dx. doi. org/10. 1038/nature02885.
46. Garcia DM, Jarosz DF. Rebels with a cause: molecular features and physiological consequences of yeast prions. FEMS Yeast Res 2014; 14: 136-47; PMID: 25667942; http://dx. doi. org/10. 1111/1567-1364. 12116.
47. Gitler AD, Shorter J. RNA-binding proteins with prion-like domains in ALS and FTLD-U. Prion 2011; 5: 179-87; PMID: 21847013; http://dx. doi. org/10. 4161/pri. 5. 3. 17230.
48. Johnson BS, Snead D, Lee JJ, McCaffery JM, Shorter J, Gitler AD. TDP-43 is intrinsically aggregationprone, and amyotrophic lateral sclerosis-linked mutations accelerate aggregation and increase toxicity. J Biol Chem 2009; 284: 20329-39; PMID: 19465477; http://dx. doi. org/10. 1074/jbc. M109. 010264.
49. Sun Z, Diaz Z, Fang X, Hart MP, Chesi A, Shorter J, Gitler AD. Molecular determinants and genetic modifiers of aggregation and toxicity for the ALS disease protein FUS/TLS. PLoS Biol 2011; 9: e1000614; PMID: 21541367; http://dx. doi. org/10. 1371/journal. pbio. 1000614.
50. King OD, Gitler AD, Shorter J. The tip of the iceberg: RNA-binding proteins with prion-like domains in neurodegenerative disease. Brain Res 2012; 1462: 61-80; PMID: 22445064; http://dx. doi. org/10. 1016/j. brainres. 2012. 01. 016.
51. Li YR, King OD, Shorter J, Gitler AD. Stress granules as crucibles of ALS pathogenesis. J Cell Biol 2013; 201: 361-72; PMID: 23629963; http://dx. doi. org/10. 1083/jcb. 201302044.
52. Kim HJ, Kim NC, Wang YD, Scarborough EA, Moore J, Diaz Z, MacLea KS, Freibaum B, Li S, Molliex A, et al. Mutations in prion-like domains in hnRNPA2B1 and hnRNPA1 cause multisystem proteinopathy and ALS. Nature 2013; 495: 467-73; PMID: 23455423; http://dx. doi. org/10. 1038/nature11922.
53. Shorter J, Taylor JP. Disease mutations in the prionlike domains of hnRNPA1 and hnRNPA2B1 introduce potent steric zippers that drive excess RNP granule assembly. Rare Diseases 2013; 1: e25200; http://dx. doi. org/10. 4161/rdis. 25200.
54. Halfmann R, Lindquist S. Epigenetics in the extreme: prions and the inheritance of environmentally acquired traits. Science 2010; 330: 629-32; PMID: 21030648; http://dx. doi. org/10. 1126/science. 1191081.
55. Heinrich SU, Lindquist S. Protein-only mechanism induces self-perpetuating changes in the activity of neuronal Aplysia cytoplasmic polyadenylation element binding protein (CPEB). Proc Natl Acad Sci U S A 2011; 108: 2999-3004; PMID: 21270333; http://dx. doi. org/10. 1073/pnas. 1019368108.
56. Si K, Choi YB, White-Grindley E, Majumdar A, Kandel ER. Aplysia CPEB can form prion-like multimers in sensory neurons that contribute to long-term facilitation. Cell 2010; 140: 421-35; PMID: 20144764; http://dx. doi. org/10. 1016/j. cell. 2010. 01. 008.
57. Si K, Lindquist S, Kandel E. A possible epigenetic mechanism for the persistence of memory. Cold Spring Harb Symp Quant Biol 2004; 69: 497-8; PMID: 16117686; http://dx. doi. org/10. 1101/sqb. 2004. 69. 497.
58. Si K, Giustetto M, Etkin A, Hsu R, Janisiewicz AM, Miniaci MC, Kim JH, Zhu H, Kandel ER. A neuronal isoform of CPEB regulates local protein synthesis and stabilizes synapse-specific long-term facilitation in aplysia. Cell 2003; 115: 893-904; PMID: 14697206; http://dx. doi. org/10. 1016/S0092-8674(03)01021-3.
59. Si K, Lindquist S, Kandel ER. A neuronal isoform of the aplysia CPEB has prion-like properties. Cell 2003; 115: 879-91; PMID: 14697205; http://dx. doi. org/10. 1016/S0092-8674(03)01020-1.
60. Majumdar A, Cesario WC, White-Grindley E, Jiang H, Ren F, Khan MR, Li L, Choi EM, Kannan K, Guo F, et al. Critical role of amyloid-like oligomers of Drosophila Orb2 in the persistence of memory. Cell 2012; 148: 515-29; PMID: 22284910; http://dx. doi. org/10. 1016/j. cell. 2012. 01. 004.
61. Jackrel ME, DeSantis ME, Martinez BA, Castellano LM, Stewart RM, Caldwell KA, Caldwell GA, Shorter J. Potentiated Hsp104 variants antagonize diverse proteotoxic misfolding events. Cell 2014; 156: 170-82; PMID: 24439375; http://dx. doi. org/10. 1016/j. cell. 2013. 11. 047.
62. Jackrel ME, Shorter J. Reversing deleterious protein aggregation with re-engineered protein disaggregases. Cell Cycle 2014; 13: 1379-83; PMID: 24694655; http://dx. doi. org/10. 4161/cc. 28709.
63. Jackrel ME, Shorter J. Potentiated Hsp104 variants suppress toxicity of diverse neurodegenerative disease-linked proteins. Dis Model Mech 2014; 7: 1175-84; PMID: 25062688; http://dx. doi. org/10. 1242/dmm. 016113.
64. Jackrel ME, Tariq A, Yee K, Weitzman R, Shorter J. Isolating potentiated Hsp104 variants using yeast proteinopathy models. J Vis Exp 2014; 93: e52089; PMID: 25407485.
65. Glover JR, Lindquist S. Hsp104, Hsp70, and Hsp40: a novel chaperone system that rescues previously aggregated proteins. Cell 1998; 94: 73-82; PMID: 9674429; http://dx. doi. org/10. 1016/S0092-8674(00)81223-4.
66. Parsell DA, Kowal AS, Singer MA, Lindquist S. Protein disaggregation mediated by heat-shock protein Hsp104. Nature 1994; 372: 475-8; PMID: 7984243; http://dx. doi. org/10. 1038/372475a0.
67. DeSantis ME, Shorter J. The elusive middle domain of Hsp104 and ClpB: location and function. Biochim Biophys Acta 2012; 1823: 29-39; PMID: 21843558; http://dx. doi. org/10. 1016/j. bbamcr. 2011. 07. 014.
68. Parsell DA, Kowal AS, Lindquist S. Saccharomyces cerevisiae Hsp104 protein. Purification and characterization of ATP-induced structural changes. J Biol Chem 1994; 269: 4480-7; PMID: 8308017.
69. Tessarz P, Mogk A, Bukau B. Substrate threading through the central pore of the Hsp104 chaperone as a common mechanism for protein disaggregation and prion propagation. Mol Microbiol 2008; 68: 87-97; PMID: 18312264; http://dx. doi. org/10. 1111/j. 1365-2958. 2008. 06135. x.
70. Haslberger T, Zdanowicz A, Brand I, Kirstein J, Turgay K, Mogk A, Bukau B. Protein disaggregation by the AAAC chaperone ClpB involves partial threading of looped polypeptide segments. Nat Struct Mol Biol 2008; 15: 641-50; PMID: 18488042; http://dx. doi. org/10. 1038/nsmb. 1425.
71. Lum R, Niggemann M, Glover JR. Peptide and protein binding in the axial channel of Hsp104. Insights into the mechanism of protein unfolding. J Biol Chem 2008; 283: 30139-50; PMID: 18755692; http://dx. doi. org/10. 1074/jbc. M804849200.
72. Lum R, Tkach JM, Vierling E, Glover JR. Evidence for an unfolding/threading mechanism for protein disaggregation by Saccharomyces cerevisiae Hsp104. J Biol Chem 2004; 279: 29139-46; PMID: 15128736; http://dx. doi. org/10. 1074/jbc. M403777200.
73. Shorter J. The mammalian disaggregase machinery: Hsp110 synergizes with Hsp70 and Hsp40 to catalyze protein disaggregation and reactivation in a cell-free system. PLoS One 2011; 6: e26319; PMID: 22022600; http://dx. doi. org/10. 1371/journal. pone. 0026319.
74. Rampelt H, Kirstein-Miles J, Nillegoda NB, Chi K, Scholz SR, Morimoto RI, Bukau B. Metazoan Hsp70 machines use Hsp110 to power protein disaggregation. EMBO J 2012; 31: 4221-35; PMID: 22990239; http://dx. doi. org/10. 1038/emboj. 2012. 264.
75. Sweeny EA, Shorter J. Prion proteostasis: Hsp104 meets its supporting cast. Prion 2008; 2: 135-40; PMID: 19242125; http://dx. doi. org/10. 4161/pri. 2. 4. 7952.
76. Torrente MP, Shorter J. The metazoan protein disaggregase and amyloid depolymerase system: Hsp110, Hsp70, Hsp40, and small heat shock proteins. Prion 2013; 7: 457-63; PMID: 24401655; http://dx. doi. org/10. 4161/pri. 27531.
77. Doyle SM, Shorter J, Zolkiewski M, Hoskins JR, Lindquist S, Wickner S. Asymmetric deceleration of ClpB or Hsp104 ATPase activity unleashes protein-remodeling activity. Nat Struct Mol Biol 2007; 14: 114-22; PMID: 17259993; http://dx. doi. org/10. 1038/nsmb1198.
78. Lo Bianco C, Shorter J, Regulier E, Lashuel H, Iwatsubo T, Lindquist S, Aebischer P. Hsp104 antagonizes alpha-synuclein aggregation and reduces dopaminergic degeneration in a rat model of Parkinson disease. J Clin Invest 2008; 118: 3087-97; PMID: 18704197; http://dx. doi. org/10. 1172/JCI35781.
79. Shorter J, Lindquist S. Hsp104 catalyzes formation and elimination of self-replicating Sup35 prion conformers. Science 2004; 304: 1793-7; PMID: 15155912; http://dx. doi. org/10. 1126/science. 1098007.
80. Shorter J, Lindquist S. Destruction or potentiation of different prions catalyzed by similar Hsp104 remodeling activities. Mol Cell 2006; 23: 425-38; PMID: 16885031; http://dx. doi. org/10. 1016/j. molcel. 2006. 05. 042.
81. Shorter J, Lindquist S. Hsp104, Hsp70 and Hsp40 interplay regulates formation, growth and elimination of Sup35 prions. Embo J 2008; 27: 2712-24; PMID: 18833196; http://dx. doi. org/10. 1038/emboj. 2008. 194.
82. Wendler P, Shorter J, Plisson C, Cashikar AG, Lindquist S, Saibil HR. Atypical AAAC subunit packing creates an expanded cavity for disaggregation by the protein-remodeling factor Hsp104. Cell 2007; 131: 1366-77; PMID: 18160044; http://dx. doi. org/10. 1016/j. cell. 2007. 10. 047.
83. Wendler P, Shorter J, Snead D, Plisson C, Clare DK, Lindquist S, Saibil HR. Motor mechanism for protein threading through Hsp104. Mol Cell 2009; 34: 81-92; PMID: 19362537; http://dx. doi. org/10. 1016/j. molcel. 2009. 02. 026.
84. Duennwald ML, Echeverria AL, Shorter J. Small Heat Shock Proteins Potentiate Amyloid Dissolution by Protein Disaggregases from Yeast and Humans. PLoS Biol 2012; 9 e1001346;; http://dx. doi. org/10. 1371/journal. pbio. 1001346.
85. DiSalvo S, Derdowski A, Pezza JA, Serio TR. Dominant prion mutants induce curing through pathways that promote chaperone-mediated disaggregation. Nat Struct Mol Biol 2011; 18: 486-92; PMID: 21423195; http://dx. doi. org/10. 1038/nsmb. 2031.
86. Park YN, Zhao X, Yim YI, Todor H, Ellerbrock R, Reidy M, Eisenberg E, Masison DC, Greene LE. Hsp104 overexpression cures Saccharomyces cerevisiae [PSIC] by causing dissolution of the prion seeds. Eukaryot Cell 2014;; 13: 635-47.
87. Klaips CL, Hochstrasser ML, Langlois CR, Serio TR. Spatial quality control bypasses cell-based limitations on proteostasis to promote prion curing. Elife 2014; 3; PMID: 25490068; http://dx. doi. org/10. 7554/eLife. 04288.
88. Liu YH, Han YL, Song J, Wang Y, Jing YY, Shi Q, Tian C, Wang ZY, Li CP, Han J, et al. Heat shock protein 104 inhibited the fibrillization of prion peptide 106-126 and disassembled prion peptide 106-126 fibrils in vitro. Int J Biochem Cell Biol 2011; 43: 768-74; PMID: 21296677; http://dx. doi. org/10. 1016/j. biocel. 2011. 01. 022.
89. Shorter J. Emergence and natural selection of drugresistant prions. Mol Biosyst 2010; 6: 1115-30; PMID: 20422111; http://dx. doi. org/10. 1039/c004550k.
90. Chernoff YO, Lindquist SL, Ono B, Inge-Vechtomov SG, Liebman SW. Role of the chaperone protein Hsp104 in propagation of the yeast prion-like factor [psiC]. Science 1995; 268: 880-4; PMID: 7754373; http://dx. doi. org/10. 1126/science. 7754373.
91. DeSantis ME, Shorter J. Hsp104 drives "proteinonly" positive selection of Sup35 prion strains encoding strong [PSI(C)]. Chem Biol 2012; 19: 1400-10; PMID: 23177195; http://dx. doi. org/10. 1016/j. chembiol. 2012. 09. 013.
92. Cushman-Nick M, Bonini NM, Shorter J. Hsp104 suppresses polyglutamine-induced degeneration post onset in a drosophila MJD/SCA3 model. PLoS Genet 2013; 9: e1003781; PMID: 24039611; http://dx. doi. org/10. 1371/journal. pgen. 1003781.
93. Satyal SH, Schmidt E, Kitagawa K, Sondheimer N, Lindquist S, Kramer JM, Morimoto RI. Polyglutamine aggregates alter protein folding homeostasis in Caenorhabditis elegans. Proc Natl Acad Sci U S A 2000; 97: 5750-5; PMID: 10811890; http://dx. doi. org/10. 1073/pnas. 100107297.
94. Vacher C, Garcia-Oroz L, Rubinsztein DC. Overexpression of yeast hsp104 reduces polyglutamine aggregation and prolongs survival of a transgenic mouse model of Huntington's disease. Hum Mol Genet 2005; 14: 3425-33; PMID: 16204350; http://dx. doi. org/10. 1093/hmg/ddi372.
95. Dandoy-Dron F, Bogdanova A, Beringue V, Bailly Y, Tovey MG, Laude H, Dron M. Infection by ME7 prion is not modified in transgenic mice expressing the yeast chaperone Hsp104 in neurons. Neurosci Lett 2006; 405: 181-5; PMID: 16884849; http://dx. doi. org/10. 1016/j. neulet. 2006. 05. 066.
96. Murray AN, Kelly JW. Hsp104 gives clients the individual attention they need. Cell 2012; 151: 695-7; PMID: 23141530; http://dx. doi. org/10. 1016/j. cell. 2012. 10. 033.
97. Escusa-Toret S, Vonk WI, Frydman J. Spatial sequestration of misfolded proteins by a dynamic chaperone pathway enhances cellular fitness during stress. Nat Cell Biol 2013; 15: 1231-43; PMID: 24036477; http://dx. doi. org/10. 1038/ncb2838.
98. Shorter J. Amyloid remodeling by Hsp104. In: Witt SN, ed. Protein Chaperones and Protection from Neurodegeneration. Hoboken, NJ: John Wiley & Sons, Inc., 2011; 235-59.
99. Hallett M, Albanese A, Dressler D, Segal KR, Simpson DM, Truong D, Jankovic J. Evidencebased review and assessment of botulinum neurotoxin for the treatment of movement disorders. Toxicon 2013; 67: 94-114; PMID: 23380701; http://dx. doi. org/10. 1016/j. toxicon. 2012. 12. 004.
100. Naumann M, Dressler D, Hallett M, Jankovic J, Schiavo G, Segal KR, Truong D. Evidence-based review and assessment of botulinum neurotoxin for the treatment of secretory disorders. Toxicon 2013; 67: 141-52; PMID: 23178324; http://dx. doi. org/10. 1016/j. toxicon. 2012. 10. 020.
101. Chancellor MB, Elovic E, Esquenazi A, Naumann M, Segal KR, Schiavo G, Smith CP, Ward AB. Evidence-based review and assessment of botulinum neurotoxin for the treatment of urologic conditions. Toxicon 2013; 67: 129-40; PMID: 23415704; http://dx. doi. org/10. 1016/j. toxicon. 2013. 01. 020.
102. Osborne SL, Latham CF, Wen PJ, Cavaignac S, Fanning J, Foran PG, Meunier FA. The Janus faces of botulinum neurotoxin: sensational medicine and deadly biological weapon. J Neurosci Res 2007; 85: 1149-58; PMID: 17387703; http://dx. doi. org/10. 1002/jnr. 21171.
103. Tighe AP, Schiavo G. Botulinum neurotoxins: mechanism of action. Toxicon 2013; 67: 87-93; PMID: 23201505; http://dx. doi. org/10. 1016/j. toxicon. 2012. 11. 011.
104. DeSantis ME, Leung EH, Sweeny EA, Jackrel ME, Cushman-Nick M, Neuhaus-Follini A, Vashist S, Sochor MA, Knight MN, Shorter J. Operational plasticity enables hsp104 to disaggregate diverse amyloid and nonamyloid clients. Cell 2012; 151: 778-93; PMID: 23141537; http://dx. doi. org/10. 1016/j. cell. 2012. 09. 038.
105. Carroni M, Kummer E, Oguchi Y, Wendler P, Clare DK, Sinning I, Kopp J, Mogk A, Bukau B, Saibil HR. Head-to-tail interactions of the coiled-coil domains regulate ClpB activity and cooperation with Hsp70 in protein disaggregation. Elife (Cambridge) 2014; 3: e02481.
106. Lee S, Sielaff B, Lee J, Tsai FT. CryoEM structure of Hsp104 and its mechanistic implication for protein disaggregation. Proc Natl Acad Sci U S A 2010; 107: 8135-40; PMID: 20404203; http://dx. doi. org/10. 1073/pnas. 1003572107.
107. DeSantis ME, Sweeny EA, Snead D, Leung EH, Go MS, Gupta K, Wendler P, Shorter J. Conserved distal loop residues in the Hsp104 and ClpB middle domain contact nucleotide-binding domain 2 and enable Hsp70-dependent protein disaggregation. J Biol Chem 2014; 289: 848-67; PMID: 24280225; http://dx. doi. org/10. 1074/jbc. M113. 520759.
108. Saibil H. Chaperone machines for protein folding, unfolding and disaggregation. Nat Rev Mol Cell Biol 2013; 14: 630-42; PMID: 24026055; http://dx. doi. org/10. 1038/nrm3658.
109. Chen-Plotkin AS, Lee VM, Trojanowski JQ. TAR DNA-binding protein 43 in neurodegenerative disease. Nat Rev Neurol 2010; 6: 211-20; PMID: 20234357; http://dx. doi. org/10. 1038/nrneurol. 2010. 18.
110. Mackenzie IR, Rademakers R, Neumann M. TDP-43 and FUS in amyotrophic lateral sclerosis and frontotemporal dementia. Lancet Neurol 2010; 9: 995-1007; PMID: 20864052; http://dx. doi. org/10. 1016/S1474-4422(10)70195-2.
111. McCann H, Stevens CH, Cartwright H, Halliday GM. alpha-Synucleinopathy phenotypes. Parkinsonism Relat Disord 2014; 20 Suppl 1: S62-7;; http://dx. doi. org/10. 1016/S1353-8020(13)70017-8.
112. Auluck PK, Caraveo G, Lindquist S. alpha-Synuclein: membrane interactions and toxicity in Parkinson's disease. Annu Rev Cell Dev Biol 2010; 26: 211-33; PMID: 20500090; http://dx. doi. org/10. 1146/annurev. cellbio. 042308. 113313.
113. Johnson BS, McCaffery JM, Lindquist S, Gitler AD. A yeast TDP-43 proteinopathy model: Exploring the molecular determinants of TDP-43 aggregation and cellular toxicity. Proc Natl Acad Sci U S A 2008; 105: 6439-44; PMID: 18434538; http://dx. doi. org/10. 1073/pnas. 0802082105.
114. Ju S, Tardiff DF, Han H, Divya K, Zhong Q, Maquat LE, Bosco DA, Hayward LJ, Brown RH, Jr., Lindquist S, et al. A yeast model of FUS/TLSdependent cytotoxicity. PLoS Biol 2011; 9: e1001052; PMID: 21541368; http://dx. doi. org/10. 1371/journal. pbio. 1001052.
115. Outeiro TF, Lindquist S. Yeast cells provide insight into a-synuclein biology and pathobiology. Science 2003; 302: 1772-5; PMID: 14657500; http://dx. doi. org/10. 1126/science. 1090439.
116. Cooper AA, Gitler AD, Cashikar A, Haynes CM, Hill KJ, Bhullar B, Liu K, Xu K, Strathearn KE, Liu F, et al. Alpha-synuclein blocks ER-Golgi traffic and Rab1 rescues neuron loss in Parkinson's models. Science 2006; 313: 324-8; PMID: 16794039; http://dx. doi. org/10. 1126/science. 1129462.
117. Gitler AD. Beer and bread to brains and beyond: can yeast cells teach us about neurodegenerative disease? Neurosignals 2008; 16: 52-62; PMID: 18097160; http://dx. doi. org/10. 1159/000109759.
118. Tenreiro S, Munder MC, Alberti S, Outeiro TF. Harnessing the power of yeast to unravel the molecular basis of neurodegeneration. J Neurochem 2013; 127: 438-52; PMID: 23600759; http://dx. doi. org/10. 1111/jnc. 12271.
119. Gitcho MA, Bigio EH, Mishra M, Johnson N, Weintraub S, Mesulam M, Rademakers R, Chakraverty S, Cruchaga C, Morris JC, et al. TARDBP 3'-UTR variant in autopsy-confirmed frontotemporal lobar degeneration with TDP-43 proteinopathy. Acta Neuropathol 2009; 118: 633-45; PMID: 19618195; http://dx. doi. org/10. 1007/s00401-009-0571-7.
120. Dini Modigliani S, Morlando M, Errichelli L, Sabatelli M, Bozzoni I. An ALS-associated mutation in the FUS 3'-UTR disrupts a microRNA-FUS regulatory circuitry. Nat Commun 2014; 5: 4335; PMID: 25004804.
121. Sabatelli M, Moncada A, Conte A, Lattante S, Marangi G, Luigetti M, Lucchini M, Mirabella M, Romano A, Del Grande A, et al. Mutations in the 3' untranslated region of FUS causing FUS overexpression are associated with amyotrophic lateral sclerosis. Hum Mol Genet 2013; 22: 4748-55; PMID: 23847048; http://dx. doi. org/10. 1093/hmg/ddt328.
122. Singleton AB, Farrer M, Johnson J, Singleton A, Hague S, Kachergus J, Hulihan M, Peuralinna T, Dutra A, Nussbaum R, et al. alpha-Synuclein locus triplication causes Parkinson's disease. Science 2003; 302: 841; PMID: 14593171; http://dx. doi. org/10. 1126/science. 1090278.
123. Chartier-Harlin MC, Kachergus J, Roumier C, Mouroux V, Douay X, Lincoln S, Levecque C, Larvor L, Andrieux J, Hulihan M, et al. Alpha-synuclein locus duplication as a cause of familial Parkinson's disease. Lancet 2004; 364: 1167-9; PMID: 15451224; http://dx. doi. org/10. 1016/S0140-6736(04)17103-1.
124. Shin CW, Kim HJ, Park SS, Kim SY, Kim JY, Jeon BS. Two Parkinson's disease patients with alpha-synuclein gene duplication and rapid cognitive decline. Mov Disord 2010; 25: 957-9; PMID: 20222138; http://dx. doi. org/10. 1002/mds. 23043.
125. Ahn TB, Kim SY, Kim JY, Park SS, Lee DS, Min HJ, Kim YK, Kim SE, Kim JM, Kim HJ, et al. alpha-Synuclein gene duplication is present in sporadic Parkinson disease. Neurology 2008; 70: 43-9; PMID: 17625105; http://dx. doi. org/10. 1212/01. wnl. 0000271080. 53272. c7.
126. Jackson KL, Dayton RD, Orchard EA, Ju S, Ringe D, Petsko GA, Maquat LE, Klein RL. Preservation of forelimb function by UPF1 gene therapy in a rat model of TDP-43-induced motor paralysis. Gene Ther 2015; 22(1): 20-28. doi: 10. 1038/gt. 2014. 101.
127. Armakola M, Higgins MJ, Figley MD, Barmada SJ, Scarborough EA, Diaz Z, Fang X, Shorter J, Krogan NJ, Finkbeiner S, et al. Inhibition of RNA lariat debranching enzyme suppresses TDP-43 toxicity in ALS disease models. Nat Genet 2012; 44: 1302-9; PMID: 23104007; http://dx. doi. org/10. 1038/ng. 2434.
128. Elden AC, Kim HJ, Hart MP, Chen-Plotkin AS, Johnson BS, Fang X, Armakola M, Geser F, Greene R, Lu MM, et al. Ataxin-2 intermediate-length polyglutamine expansions are associated with increased risk for ALS. Nature 2010; 466: 1069-75; PMID: 20740007; http://dx. doi. org/10. 1038/nature09320.
129. Kim HJ, Raphael AR, LaDow ES, McGurk L, Weber RA, Trojanowski JQ, Lee VM, Finkbeiner S, Gitler AD, Bonini NM. Therapeutic modulation of eIF2alpha phosphorylation rescues TDP-43 toxicity in amyotrophic lateral sclerosis disease models. Nat Genet 2014; 46: 152-60; PMID: 24336168; http://dx. doi. org/10. 1038/ng. 2853.
130. Narayan P, Ehsani S, Lindquist S. Combating neurodegenerative disease with chemical probes and model systems. Nat Chem Biol 2014; 10: 911-20; PMID: 25325702; http://dx. doi. org/10. 1038/nchembio. 1663.
131. Gitler AD, Chesi A, Geddie ML, Strathearn KE, Hamamichi S, Hill KJ, Caldwell KA, Caldwell GA, Cooper AA, Rochet JC, et al. Alpha-synuclein is part of a diverse and highly conserved interaction network that includes PARK9 and manganese toxicity. Nat Genet 2009; 41: 308-15; PMID: 19182805; http://dx. doi. org/10. 1038/ng. 300.
132. Yeger-Lotem E, Riva L, Su LJ, Gitler AD, Cashikar AG, King OD, Auluck PK, Geddie ML, Valastyan JS, Karger DR, et al. Bridging high-throughput genetic and transcriptional data reveals cellular responses to alpha-synuclein toxicity. Nat Genet 2009; 41: 316-23; PMID: 19234470; http://dx. doi. org/10. 1038/ng. 337.
133. Caraveo G, Auluck PK, Whitesell L, Chung CY, Baru V, Mosharov EV, Yan X, Ben-Johny M, Soste M, Picotti P, et al. Calcineurin determines toxic versus beneficial responses to alpha-synuclein. Proc Natl Acad Sci U S A 2014; 111: E3544-52; PMID: 25122673; http://dx. doi. org/10. 1073/pnas. 1413201111.
134. Chung CY, Khurana V, Auluck PK, Tardiff DF, Mazzulli JR, Soldner F, Baru V, Lou Y, Freyzon Y, Cho S, et al. Identification and rescue of alpha-synuclein toxicity in Parkinson patient-derived neurons. Science 2013; 342: 983-7; PMID: 24158904; http://dx. doi. org/10. 1126/science. 1245296.
135. Su LJ, Auluck PK, Outeiro TF, Yeger-Lotem E, Kritzer JA, Tardiff DF, Strathearn KE, Liu F, Cao S, Hamamichi S, et al. Compounds from an unbiased chemical screen reverse both ER-to-Golgi trafficking defects and mitochondrial dysfunction in Parkinson's disease models. Dis Model Mech 2010; 3: 194-208; PMID: 20038714; http://dx. doi. org/10. 1242/dmm. 004267.
136. Tardiff DF, Jui NT, Khurana V, Tambe MA, Thompson ML, Chung CY, Kamadurai HB, Kim HT, Lancaster AK, Caldwell KA, et al. Yeast reveal a "druggable" Rsp5/Nedd4 network that ameliorates alpha-synuclein toxicity in neurons. Science 2013; 342: 979-83; PMID: 24158909; http://dx. doi. org/10. 1126/science. 1245321.
137. Tardiff DF, Khurana V, Chung CY, Lindquist S. From yeast to patient neurons and back again: powerful new discovery platform. Mov Disord 2014; 29: 1231-40; PMID: 25131316; http://dx. doi. org/10. 1002/mds. 25989.
138. Tardiff DF, Tucci ML, Caldwell KA, Caldwell GA, Lindquist S. Different 8-hydroxyquinolines protect models of TDP-43 protein, alpha-synuclein, and polyglutamine proteotoxicity through distinct mechanisms. J Biol Chem 2012; 287: 4107-20; PMID: 22147697; http://dx. doi. org/10. 1074/jbc. M111. 308668.
139. Bonini NM, Gitler AD. Model organisms reveal insight into human neurodegenerative disease: ataxin-2 intermediate-length polyglutamine expansions are a risk factor for ALS. J Mol Neurosci 2011; 45: 676-83; PMID: 21660502; http://dx. doi. org/10. 1007/s12031-011-9548-9.
140. Gispert S, Kurz A, Waibel S, Bauer P, Liepelt I, Geisen C, Gitler AD, Becker T, Weber M, Berg D, et al. The modulation of Amyotrophic Lateral Sclerosis risk by ataxin-2 intermediate polyglutamine expansions is a specific effect. Neurobiol Dis 2012; 45: 356-61; PMID: 21889984; http://dx. doi. org/10. 1016/j. nbd. 2011. 08. 021.
141. Hart MP, Brettschneider J, Lee VM, Trojanowski JQ, Gitler AD. Distinct TDP-43 pathology in ALS patients with ataxin 2 intermediate-length polyQ expansions. Acta Neuropathol 2012; 124: 221-30; PMID: 22526021; http://dx. doi. org/10. 1007/s00401-012-0985-5.
142. Hart MP, Gitler AD. ALS-associated ataxin 2 polyQ expansions enhance stress-induced caspase 3 activation and increase TDP-43 pathological modifications. J Neurosci 2012; 32: 9133-42; PMID: 22764223; http://dx. doi. org/10. 1523/JNEUROSCI. 0996-12. 2012.
143. Lee T, Li YR, Chesi A, Hart MP, Ramos D, Jethava N, Hosangadi D, Epstein J, Hodges B, Bonini NM, et al. Evaluating the prevalence of polyglutamine repeat expansions in amyotrophic lateral sclerosis. Neurology 2011; 76: 2062-5; PMID: 21562248; http://dx. doi. org/10. 1212/WNL. 0b013e31821f4447.
144. Lee T, Li YR, Ingre C, Weber M, Grehl T, Gredal O, de Carvalho M, Meyer T, Tysnes OB, Auburger G, et al. Ataxin-2 intermediate-length polyglutamine expansions in European ALS patients. Hum Mol Genet 2011; 20: 1697-700; PMID: 21292779; http://dx. doi. org/10. 1093/hmg/ddr045.
145. Yu Z, Zhu Y, Chen-Plotkin AS, Clay-Falcone D, McCluskey L, Elman L, Kalb RG, Trojanowski JQ, Lee VM, Van Deerlin VM, et al. PolyQ repeat expansions in ATXN2 associated with ALS are CAA interrupted repeats. PLoS One 2011; 6: e17951; PMID: 21479228; http://dx. doi. org/10. 1371/journal. pone. 0017951.
146. Couthouis J, Hart MP, Erion R, King OD, Diaz Z, Nakaya T, Ibrahim F, Kim HJ, Mojsilovic-Petrovic J, Panossian S, et al. Evaluating the role of the FUS/TLS-related gene EWSR1 in amyotrophic lateral sclerosis. Hum Mol Genet 2012; 21: 2899-911; PMID: 22454397; http://dx. doi. org/10. 1093/hmg/dds116.
147. Couthouis J, Hart MP, Shorter J, DeJesus-Hernandez M, Erion R, Oristano R, Liu AX, Ramos D, Jethava N, Hosangadi D, et al. A yeast functional screen predicts new candidate ALS disease genes. Proc Natl Acad Sci U S A 2011; 108: 20881-90; PMID: 22065782; http://dx. doi. org/10. 1073/pnas. 1109434108.
148. Meriin AB, Zhang X, He X, Newnam GP, Chernoff YO, Sherman MY. Huntington toxicity in yeast model depends on polyglutamine aggregation mediated by a prion-like protein Rnq1. J Cell Biol 2002; 157: 997-1004; PMID: 12058016; http://dx. doi. org/10. 1083/jcb. 200112104.
149. Duennwald ML, Jagadish S, Giorgini F, Muchowski PJ, Lindquist S. A network of protein interactions determines polyglutamine toxicity. Proc Natl Acad Sci U S A 2006; 103: 11051-6; PMID: 16832049; http://dx. doi. org/10. 1073/pnas. 0604548103.
150. Gokhale KC, Newnam GP, Sherman MY, Chernoff YO. Modulation of prion-dependent polyglutamine aggregation and toxicity by chaperone proteins in the yeast model. J Biol Chem 2005; 280: 22809-18; PMID: 15824100; http://dx. doi. org/10. 1074/jbc. M500390200.
151. Cashikar AG, Schirmer EC, Hattendorf DA, Glover JR, Ramakrishnan MS, Ware DM, Lindquist SL. Defining a pathway of communication from the Cterminal peptide binding domain to the N-terminal ATPase domain in a AAA protein. Mol Cell 2002; 9: 751-60; PMID: 11983167; http://dx. doi. org/10. 1016/S1097-2765(02)00499-9.
152. Sielaff B, Tsai FT. The M-domain controls Hsp104 protein remodeling activity in an Hsp70/Hsp40-dependent manner. J Mol Biol 2010; 402: 30-7; PMID: 20654624; http://dx. doi. org/10. 1016/j. jmb. 2010. 07. 030.
153. Miot M, Reidy M, Doyle SM, Hoskins JR, Johnston DM, Genest O, Vitery MC, Masison DC, Wickner S. Species-specific collaboration of heat shock proteins (Hsp) 70 and 100 in thermotolerance and protein disaggregation. Proc Natl Acad Sci U S A 2011; 108: 6915-20; PMID: 21474779; http://dx. doi. org/10. 1073/pnas. 1102828108.
154. Lee J, Kim JH, Biter AB, Sielaff B, Lee S, Tsai FT. Heat shock protein (Hsp) 70 is an activator of the Hsp104 motor. Proc Natl Acad Sci U S A 2013; 110: 8513-8; PMID: 23650362; http://dx. doi. org/10. 1073/pnas. 1217988110.
155. Schirmer EC, Homann OR, Kowal AS, Lindquist S. Dominant gain-of-function mutations in Hsp104p reveal crucial roles for the middle region. Mol Biol Cell 2004; 15: 2061-72; PMID: 14978213; http://dx. doi. org/10. 1091/mbc. E02-08-0502.
156. Sweeny EA, Jackrel ME, Go MS, Sochor MA, Razzo BM, DeSantis ME, Gupta K, Shorter J. The Hsp104 N-Terminal Domain Enables Disaggregase Plasticity and Potentiation. Mol Cell 2015; 57(5): 836-849. doi: 10. 1016/j. molcel. 2014. 12. 021; PMID: 25620563.
157. Qiu H, Lee S, Shang Y, Wang WY, Au KF, Kamiya S, Barmada SJ, Finkbeiner S, Lui H, Carlton CE, et al. ALS-associated mutation FUS-R521+ causes DNA damage and RNA splicing defects. J Clin Invest 2014; 124: 981-99; PMID: 24509083; http://dx. doi. org/10. 1172/JCI72723.
158. Swarup V, Phaneuf D, Bareil C, Robertson J, Rouleau GA, Kriz J, Julien JP. Pathological hallmarks of amyotrophic lateral sclerosis/frontotemporal lobar degeneration in transgenic mice produced with TDP-43 genomic fragments. Brain 2011; 134: 2610-26; PMID: 21752789; http://dx. doi. org/10. 1093/brain/awr159.
159. Pesiridis GS, Lee VM, Trojanowski JQ. Mutations in TDP-43 link glycine-rich domain functions to amyotrophic lateral sclerosis. Hum Mol Genet 2009; 18: R156-62; PMID: 19808791; http://dx. doi. org/10. 1093/hmg/ddp303.
160. Da Cruz S, Cleveland DW. Understanding the role of TDP-43 and FUS/TLS in ALS and beyond. Curr Opin Neurobiol 2011; 21: 904-19; PMID: 21813273; http://dx. doi. org/10. 1016/j. conb. 2011. 05. 029.
161. Polymeropoulos MH, Lavedan C, Leroy E, Ide SE, Dehejia A, Dutra A, Pike B, Root H, Rubenstein J, Boyer R, et al. Mutation in the a-Synuclein Gene Identified in Families with Parkinson's Disease. Science 1997; 276: 2045-7; PMID: 9197268; http://dx. doi. org/10. 1126/science. 276. 5321. 2045.
162. Zarranz JJ, Alegre J, Gomez-Esteban JC, Lezcano E, Ros R, Ampuero I, Vidal L, Hoenicka J, Rodriguez O, Atares B, et al. The new mutation, E46K, of a-synuclein causes Parkinson and Lewy body dementia. Ann Neurol 2004; 55: 164-73; PMID: 14755719; http://dx. doi. org/10. 1002/ana. 10795.
163. Conway KA, Lee SJ, Rochet JC, Ding TT, Williamson RE, Lansbury PT. Acceleration of oligomerization, not fibrillization, is a shared property of both a-synuclein mutations linked to early-onset Parkinson's disease: Implications for pathogenesis and therapy. Proc Natl Acad Sci USA 2000; 97: 571-6; PMID: 10639120; http://dx. doi. org/10. 1073/pnas. 97. 2. 571.
164. Vance C, Rogelj B, Hortobagyi T, De Vos KJ, Nishimura AL, Sreedharan J, Hu X, Smith B, Ruddy D, Wright P, et al. Mutations in FUS, an RNA processing protein, cause familial amyotrophic lateral sclerosis type 6. Science 2009; 323: 1208-11; PMID: 19251628; http://dx. doi. org/10. 1126/science. 1165942.
165. Huang EJ, Zhang J, Geser F, Trojanowski JQ, Strober JB, Dickson DW, Brown RH, Jr., Shapiro BE, Lomen-Hoerth C. Extensive FUS-immunoreactive pathology in juvenile amyotrophic lateral sclerosis with basophilic inclusions. Brain Pathol 2010; 20: 1069-76; PMID: 20579074; http://dx. doi. org/10. 1111/j. 1750-3639. 2010. 00413. x.
166. Dormann D, Rodde R, Edbauer D, Bentmann E, Fischer I, Hruscha A, Than ME, Mackenzie IR, Capell A, Schmid B, et al. ALS-associated fused in sarcoma (FUS) mutations disrupt Transportinmediated nuclear import. EMBO J 2010; 29: 2841-57; PMID: 20606625; http://dx. doi. org/10. 1038/emboj. 2010. 143.
167. Sreedharan J, Blair IP, Tripathi VB, Hu X, Vance C, Rogelj B, Ackerley S, Durnall JC, Williams KL, Buratti E, et al. TDP-43 Mutations in Familial and Sporadic Amyotrophic Lateral Sclerosis. Science 2008; 319: 1668-72; PMID: 18309045; http://dx. doi. org/10. 1126/science. 1154584.
168. Gitcho MA, Baloh RH, Chakraverty S, Mayo K, Norton JB, Levitch D, Hatanpaa KJ, White CL 3rd, Bigio EH, Caselli R, et al. TDP-43 A315T mutation in familial motor neuron disease. Ann Neurol 2008; 63: 535-8; PMID: 18288693; http://dx. doi. org/10. 1002/ana. 21344.
169. Mackenzie IRA, Neumann M. FET proteins in frontotemporal dementia and amyotrophic lateral sclerosis. Brain Res 2012; 1462: 40-3; PMID: 22261247; http://dx. doi. org/10. 1016/j. brainres. 2011. 12. 010.
170. Tan AY, Manley JL. The TET family of proteins: functions and roles in disease. J Mol Cell Biol 2009; 1: 82-92; PMID: 19783543; http://dx. doi. org/10. 1093/jmcb/mjp025.
171. Oguchi Y, Kummer E, Seyffer F, Berynskyy M, Anstett B, Zahn R, Wade RC, Mogk A, Bukau B. A tightly regulated molecular toggle controls AAAC disaggregase. Nat Struct Mol Biol 2012; 19: 1338-46; PMID: 23160353; http://dx. doi. org/10. 1038/nsmb. 2441.
172. Sanchez Y, Lindquist SL. HSP104 required for induced thermotolerance. Science 1990; 248: 1112-5; PMID: 2188365; http://dx. doi. org/10. 1126/science. 2188365.
173. Sanchez Y, Taulien J, Borkovich KA, Lindquist S. Hsp104 is required for tolerance to many forms of stress. EMBO J 1992; 11: 2357-64; PMID: 1600951.
174. Takahashi A, Hara H, Kurahashi H, Nakamura Y. A systematic evaluation of the function of the protein-remodeling factor Hsp104 in [PSIC] prion propagation in S. cerevisiae by comprehensive chromosomal mutations. Prion 2007; 1: 69-77; PMID: 19164920; http://dx. doi. org/10. 4161/pri. 1. 1. 4060.
175. Wang JD, Herman C, Tipton KA, Gross CA, Weissman JS. Directed evolution of substrate-optimized GroEL/S chaperonins. Cell 2002; 111: 1027-39; PMID: 12507429; http://dx. doi. org/10. 1016/S0092-8674(02)01198-4.
176. Quan S, Wang L, Petrotchenko EV, Makepeace KA, Horowitz S, Yang J, Zhang Y, Borchers CH, Bardwell JC. Super Spy variants implicate flexibility in chaperone action. Elife 2014; 3: e01584; PMID: 24497545; http://dx. doi. org/10. 7554/eLife. 01584.
177. Martin A, Baker TA, Sauer RT. Diverse pore loops of the AAAC ClpX machine mediate unassisted and adaptor-dependent recognition of ssrA-tagged substrates. Mol Cell 2008; 29: 441-50; PMID: 18313382; http://dx. doi. org/10. 1016/j. molcel. 2008. 02. 002.
178. Aponte RA, Zimmermann S, Reinstein J. Directed evolution of the DnaK chaperone: mutations in the lid domain result in enhanced chaperone activity. J Mol Biol 2010; 399: 154-67; PMID: 20381501; http://dx. doi. org/10. 1016/j. jmb. 2010. 03. 060.
179. Schweizer RS, Aponte RA, Zimmermann S, Weber A, Reinstein J. Fine tuning of a biological machine: DnaK gains improved chaperone activity by altered allosteric communication and substrate binding. Chembiochem 2011; 12: 1559-73; PMID: 21656889; http://dx. doi. org/10. 1002/cbic. 201000786.
180. Sharma D, Masison DC. Single methyl group determines prion propagation and protein degradation activities of yeast heat shock protein (Hsp)-70 chaperones Ssa1p and Ssa2p. Proc Natl Acad Sci U S A 2011; 108: 13665-70; PMID: 21808014; http://dx. doi. org/10. 1073/pnas. 1107421108.
181. Pratt WB, Gestwicki JE, Osawa Y, Lieberman AP. Targeting Hsp90/Hsp70-based protein quality control for treatment of adult onset neurodegenerative diseases. Annu Rev Pharmacol Toxicol 2015; 55: 353-371; doi: 10. 1146/annurevpharmtox-010814-124332.
182. Wang AM, Miyata Y, Klinedinst S, Peng HM, Chua JP, Komiyama T, Li X, Morishima Y, Merry DE, Pratt WB, et al. Activation of Hsp70 reduces neurotoxicity by promoting polyglutamine protein degradation. Nat Chem Biol 2013; 9: 112-8; PMID: 23222885; http://dx. doi. org/10. 1038/nchembio. 1140.